Core Viewpoint - A class action has been filed against Skye Bioscience, Inc. for allegedly misleading investors about the effectiveness and prospects of its lead drug candidate, nimacimab [1][2]. Group 1: Company Overview - Skye Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases [1]. - The lead product candidate of the company is nimacimab [1]. Group 2: Allegations and Impact - The complaint alleges that during the class period, Skye failed to disclose that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - On October 6, 2025, Skye announced that the nimacimab monotherapy did not achieve the primary endpoint of weight loss compared to placebo, resulting in a stock price drop of $2.85 per share, or 60%, closing at $1.90 per share [3]. Group 3: Legal Proceedings - Shareholders wishing to serve as lead plaintiff in the class action must submit their papers by January 16, 2026 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Group 1 - Nxera Pharma has achieved a second significant R&D milestone in its collaboration with AbbVie, resulting in a payment of US$10 million [1][3] - The collaboration, initiated in 2022, focuses on discovering novel medicines targeting G protein-coupled receptors (GPCRs) related to neurological diseases [2][3] - Nxera is eligible for up to US$40 million in near-term research milestones and potential total milestones of up to US$1.2 billion, along with tiered royalties on global sales [3] Group 2 - Dr. Matt Barnes, Chief Scientific Officer of Nxera, emphasized the productivity of the collaboration and the progress made in developing novel molecules for neurological disease targets [4] - The milestone payment will be recognized in the third quarter of 2025 [4] - Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines for unmet medical needs in Japan and globally [6][7] Group 3 - Nxera has an extensive pipeline of over 30 active programs targeting major unmet needs in areas such as obesity, metabolic disorders, neurology, and immunology [7] - The company employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul [8]